Ask AI
ProCE Banner Activity

CE / CME

TYK2 Inhibition in Plaque Psoriasis: Biologic Rationale and Recent Findings From AAD 2026

Clinical Thought

TYK2 inhibitors offer a targeted approach to plaque psoriasis by selectively modulating signaling pathways involved in the IL-23/IL-17 axis, which plays a central role in disease pathogenesis. Recent data presented at the AAD 2026 Annual Meeting provide further insight into the potential of TYK2 inhibition in moderate to severe plaque psoriasis. Learn how next-generation TYK2 inhibitors are showing promise for achieving faster and deeper responses compared with deucravacitinib and may further reshape the plaque psoriasis treatment landscape. Then, consider how these emerging data may inform future clinical decision-making.

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Physicians: maximum of 0.25 AMA PRA Category 1 Credit™

Nurse Practitioners/Nurses: 0.25 Nursing contact hour

Released: October 01, 2026

Expiration: September 30, 2027

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Takeda Pharmaceuticals U.S.A., Inc.

Target Audience

This program is intended for dermatology HCPs, including dermatologists, nurse practitioners (NPs), physician associates (PAs), and other HCPs who care for patients with PsO.

Program Learning Goal

The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Psoriasis.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Differentiate the efficacy, safety, and selectivity profiles of treatments targeting TYK2 versus JAK1, JAK2, and JAK3 signaling pathways in moderate to severe psoriasis

  • Summarize the recent and ongoing clinical trial data for current and emerging oral small molecule treatments for patients with moderate to severe psoriasis

  • Identify patients with psoriasis who would be appropriate candidates for oral small molecule treatment based on patient preference, efficacy, and safety

Financial Disclosures

Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Melinda Gooderham, MD, MSc, FRCPC: consultant/advisor/speaker (paid to institution): AbbVie, Amgen, Apogee, Apollo, Arcutis, Bausch Health, Boehringer Ingelheim, Coultreon, Expedition, Galderma, GSK, Jamp, Janssen, LEO, Lilly, L’Oreal, Novartis, Organon Canada, Pfizer, Regeneron, Sanofi Genzyme, Sun, Takeda, UCB, Union; researcher (paid to institution): AbbVie, Acelyrin, Alumis, Amgen, AnaptysBio, Apogee, Arcutis, Aristea, Attovia, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Dermira, Galderma, GSK, Incyte, Insmed, Jamp, Janssen, LEO, Lilly, Meiji Seika, Merck, MoonLake, Nektar, Novartis, Organon Canada, Oruka, Pfizer, Q32 Bio, Regeneron, Reistone, Sanofi Genzyme, Sun, Takeda, Tarsus, UCB, Ventyx, Vyne.

The planners and content peer reviewers from Decera Clinical Education do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 01, 2026, through September 30, 2027:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Additional Disclosures

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Generative artificial intelligence (AI) tools were used for revising or refining educational content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.25 contact hours.

Physician Associate Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until September 30, 2027. PAs should only claim credit commensurate with the extent of their participation.

IPCE Credit Designation

A logo for a credit companyAI-generated content may be incorrect.
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

CME Passport

A logo for a companyDescription automatically generated

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit cmepassport.org to create your account.